PRQR

Proqr Therapeuti

• PUBT·07/13 12:01

  ProQR CEO Daniel Anton de Boer buys 150,000 shares for $261,000

• TipRanks·07/11 13:01

  ASE, ProQR, AbSci, Ultragenyx, YPF: Insider Turmoil

• TipRanks·07/09 02:01

  ProQR CEO Makes Bold Insider Move Signaling Strong Confidence

• PUBT·07/08 18:55

  ProQR CEO Daniel Anton de Boer buys $238,500 in ordinary shares

• TipRanks·07/06 20:15

  ProQR Therapeutics registers to sell 3.03M ordinary shares for holders

• Reuters·07/06 20:11

  PROQR THERAPEUTICS NV - FILES TO REGISTER RESALE OF UP TO 3.03 MLN ORDINARY SHARES - SEC FILING

• TipRanks·07/06 12:15

  Oppenheimer Reaffirms Their Buy Rating on ProQR (PRQR)

• Seeking Alpha·07/04 14:52

  ProQR Therapeutics: Human NTCP Data Strengthens The Axiomer Thesis

• PUBT·06/30 20:01

  ProQR director Bart Filius acquires 150,000 shares for $231,000

• Dow Jones·06/29 15:11

  ProQR Therapeutics Is Maintained at Outperform by Evercore ISI Group

• Dow Jones·06/29 15:11

  ProQR Therapeutics Price Target Raised to $6.00/Share From $5.00 by Evercore ISI Group

• TipRanks·06/29 13:40

  Analysts’ Top Healthcare Picks: ProQR (PRQR), Neurogene (NGNE)

• Dow Jones·06/26 16:17

  ProQR Therapeutics Price Target Cut to $10.00/Share From $11.00 by Jones Trading

• Dow Jones·06/26 16:17

  ProQR Therapeutics Is Maintained at Buy by Jones Trading

• Dow Jones·06/26 12:58

  ProQR Therapeutics Price Target Cut to $3.00/Share From $4.00 by Chardan Capital